Eke AC, et al. - Researchers investigated the influence of 17α-hydroxyprogesterone caproate use in preventing preterm birth on the risk of gestational diabetes mellitus (GDM) via analyzing studies comparing 17α-hydroxyprogesterone caproate with unexposed control groups in women with singleton gestation and a history of a prior spontaneous preterm birth. Outcomes revealed a significantly higher incidence of abnormal glucose test results and GDM among women with singleton gestations receiving weekly 17α-hydroxyprogesterone caproate for recurrent preterm birth prevention compared with those in unexposed control groups.